🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Serina Therapeutics, Inc. SER PHARMA

Healthcare · Biotechnology · United States
https://serinatherapeutics.com
Company Profile ↓
$2.50
-53.40% 1Y
Mkt Cap$63.50M
P/E-1.34
P/B3.05
52W High$5.65
52W Low$1.28
Book Value$0.74
EPS (TTM)$-1.87

Company Overview

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.20.

Growth & Price Performance

Stock Price Performance

1 Year:-53.40%
6 Months:+57.23%
3 Months:+31.58%
1 Month:+4.17%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 28% of range
$1.28 $5.65
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross3d ago
  • RSI (14)49.16 · Neutral
Price Performance
1M+4.17%
3M+31.58%
6M+57.23%
1Y-53.40%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 55.8% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.34
Industry PE
24.83
Forward P/E
-2.38
PEG Ratio
-
Book Value
$0.74
Price to Book
3.05
P/S
inf
EV/EBITDA
-1.48
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-92.30%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.58
EPS (TTM)
$-1.87

Balance Sheet & Liquidity

Debt/Equity
0.20
Quick Ratio
6.12
Current Ratio
6.65
Debt
$3.75M
Total Assets
$27.30M
Current Assets
$26.47M
Working Capital
$2.52M

Ownership

Promoter Holding
50.75%
Chg in Prom Hold
-
FII / Inst Holding
5.55%
Chg in FII Hold
-3.92%

Financial Snapshot

Enterprise Value
$63.50M
Total Revenue (TTM)
$0
EBITDA
$-25.59M
Free Cash Flow
$-12.35M
Operating Cash Flow
$-21.14M
Shares Outstanding
25.40M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SER Serina Therapeutics, Inc. PHARMA 2.50 -1.34 $63.50M 0.00% - - - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 239.00K464.00K380.00K388.00K380.00K411.00K89.00K45.00K69.00K56.00K37.00K24.00K5.00K12.00K9.00K30.00K7.00K29.00K5.00K51.00K14.00K-00000
Cost of Revenue ---------------------------
Gross Profit 130.00K385.00K384.00K325.00K327.00K362.00K88.00K42.00K52.00K53.00K24.00K22.00K4.00K6.00K4.00K9.00K4.00K34.00K---------
Operating Expenses ----------------------5.86M5.57M6.39M6.21M6.28M
Operating Income -3.55M-2.13M-2.20M-3.12M-3.44M-3.28M-3.01M-2.37M-2.40M-2.19M-2.21M-1.67M-2.05M-1.59M-1.55M-962.00K-945.00K-1.46M-2.32M-3.87M-5.31M--5.86M-5.57M-6.39M-6.21M-6.28M
EBITDA -----------------------4.80M-6.44M-4.57M-3.10M-6.68M
Interest Expense ----------------------09.00K6.00K198.00K189.00K
Pretax Income -----------------------4.82M-6.46M-4.59M-3.32M-6.89M
Tax Provision ----------------------0---7.00K
Net Income -235.00K-1.93M-2.15M-3.13M-3.09M-3.22M-3.19M-2.69M-2.54M-2.09M-2.47M-1.96M-2.71M-2.62M-2.44M1.66M808.00K1.75M-15.02M5.20M1.41M--4.81M-6.45M-4.58M-3.34M-6.90M
Diluted EPS --------------0.07-0.060.200.110.23-5.380.510.13--0.49-0.66-0.45--0.58
R&D Expense 1.59M1.38M1.33M1.34M1.65M1.45M1.22M935.00K653.00K324.00K481.00K275.00K396.00K259.00K162.00K399.00K479.00K603.00K1.11M1.59M2.42M-2.95M3.15M3.65M-3.20M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.40M1.40M1.73M361.00K-500.00K3.00M00
Cost of Revenue ---------
Gross Profit 1.24M1.03M1.48M335.00K-----
Operating Expenses -----2.77M6.13M17.05M24.02M
Operating Income -6.66M-11.24M-12.56M-10.10M--2.27M-3.13M-17.05M-24.02M
EBITDA ------2.60M5.92M-10.49M-18.91M
Interest Expense -----15.88K558.00K526.00K213.00K
Pretax Income ------2.68M5.27M-11.21M-19.20M
Tax Provision --------18.00K
Net Income -6.58M-7.50M-12.15M-10.87M--2.68M5.27M-11.14M-19.18M
Diluted EPS ------1.230.63-1.51-1.91
R&D Expense 5.78M5.83M5.90M3.71M1.46M1.02M2.39M7.48M13.15M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -9.63M10.67M7.44M3.92M-858.04K8.97M6.72M6.95M
Current Assets ------548.58K7.62M5.68M6.08M
Cash & Equivalents 259.00K7.38M6.71M2.35M527.00K-532.23K7.62M3.67M3.06M
Inventory ----------
Receivables -----1.11K0---
Total Liabilities -1.31M2.44M4.83M9.32M-38.64M41.26M6.22M6.99M
Current Liabilities ---3.30M5.36M-437.69K1.41M2.37M3.56M
Long Term Debt ------1.62M2.98M-2.95M
Total Debt ------1.81M3.44M268.00K3.14M
Total Equity -22.38M7.28M7.45M2.22M-5.12M--37.78M-32.29M641.00K-37.00K
Shares Outstanding ------8.41M8.41M9.42M10.77M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -6.29M-8.00M-10.16M-7.82M--2.08M-2.48M-17.14M-17.95M
Investing Cash Flow 5.00K1.33M-361.00K-20.00K-980.94K-504.00K-22.00K-59.00K
Financing Cash Flow 13.28M6.00M6.26M5.96M-1.31M10.07M13.21M17.41M
Capital Expenditure -1.00K-21.00K-641.00K-20.00K--9.68K-504.00K-22.00K-59.00K
Free Cash Flow -6.29M-8.02M-10.80M-7.84M--2.09M-2.98M-17.16M-18.01M
Net Change in Cash -----217.38K7.09M-3.95M-602.00K

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 88.0%73.9%85.9%92.8%-----
Operating Margin % -474.6%-805.5%-726.8%-2,797.8%--454.1%-104.3%--
Net Margin % -468.7%-537.4%-703.4%-3,009.7%--536.4%175.6%--
ROE % -90.4%-100.7%-548.0%212.4%-7.1%-16.3%-1,738.1%51,843.2%
ROCE % ---303.0%705.3%--540.1%-41.4%-391.2%-709.0%

Shareholding Pattern

Insiders
50.75%
Institutions
5.55%
Public Float
11.27%

Top Institutional Holders

#Holder% HeldSharesValue
1 Sio Capital Management, LLC 3.94% 1.00M $2.25M
2 Vanguard Capital Management LLC 0.64% 162.20K $364.94K
3 Waverly Advisors, LLC 0.27% 67.49K $151.86K
4 Geode Capital Management, LLC 0.20% 51.01K $114.77K
5 Northern Trust Corporation 0.08% 20.77K $46.73K
6 Vanguard Fiduciary Trust Co 0.08% 20.01K $45.02K
7 Keel Point, Llc 0.08% 21.51K $48.39K
8 Avidian Wealth Enterprises, LLC 0.07% 18.80K $42.30K
9 Jane Street Group, LLC 0.06% 15.44K $34.75K
10 State Street Corporation 0.05% 12.76K $28.70K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SER

Yahoo Finance hu, 13 Aug 2026

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to the Board of Director…

Yahoo Finance hu, 23 Jul 2026

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the…

Yahoo Finance Wed, 22 Jul 2026

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, tod…

Yahoo Finance ue, 30 Jun 2026

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology…

Yahoo Finance ue, 07 Apr 2026

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucle…

Yahoo Finance hu, 02 Apr 2026

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today r…

SER — Frequently Asked Questions

What is the current share price of Serina Therapeutics, Inc. (SER)?

As of 2026-09-19 21:16 PDT, Serina Therapeutics, Inc. (SER) trades at $2.50 on NYSE American. Its 52-week range is $1.28 to $5.65.

What is the market capitalisation of SER?

Serina Therapeutics, Inc. (SER) has a market capitalisation of $63.50M on NYSE American.

What is the P/E ratio of SER?

SER trades at a trailing price-to-earnings (P/E) ratio of -1.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.05.

Is SER a good stock to buy?

This page provides a data-driven analysis of Serina Therapeutics, Inc. (SER), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space